Our findings replicate similar results recently obtained by another Italian group, that reported an improvement in insulin sensitivity and a reduction of pancreatic secretion at the end of DAA treatment and after 3 months of follow-up in a group of HCV positive, non-diabetic patients with advanced liver fibrosis [26]. The gene discussed is INS; the disease is Hepatic fibrosis.